Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease
about
Enlarged pulmonary artery is predicted by vascular injury biomarkers and is associated with WTC-lung injury in exposed fire fighters: a case-control studyChallenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the LungsBiomarkers of progression of chronic obstructive pulmonary disease (COPD)Multi-walled carbon nanotube length as a critical determinant of bioreactivity with primary human pulmonary alveolar cellsProtocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approachSystemic IL-6 Effector Response in Mediating Systemic Bone Loss Following Inhalation of Organic DustGenome-wide association analysis of blood biomarkers in chronic obstructive pulmonary diseaseStatistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.Cytokine inhibition in the treatment of COPD.Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPDIncreased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease.Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial.Long-term home noninvasive mechanical ventilation increases systemic inflammatory response in chronic obstructive pulmonary disease: a prospective observational study.Multiple biomarkers predict disease severity, progression and mortality in COPD.Significance of the microbiome in chronic obstructive pulmonary disease.Interleukin-6 and interleukin-8 blood levels' poor association with the severity and clinical profile of ex-smokers with COPD.Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease.Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.Muscarinic M3 receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in micePlasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD.Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA.Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort studyFunctional consequences for primary human alveolar macrophages following treatment with long, but not short, multiwalled carbon nanotubes.Anti-Inflammatory Effects of Lactobacillus Rahmnosus and Bifidobacterium Breve on Cigarette Smoke Activated Human Macrophages.Vascular dysfunction and chronic obstructive pulmonary disease: the role of redox balance.Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease.Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.Two-sample tests and one-way MANOVA for multivariate biomarker data with nondetects.Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease.Inflammatory markers and mortality among US adults with obstructive lung function.Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysemaProbing Cellular and Molecular Mechanisms of Cigarette Smoke-Induced Immune Response in the Progression of Chronic Obstructive Pulmonary Disease Using Multiscale Network Modeling.The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung diseaseA Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.Role of IL-6 in asthma and other inflammatory pulmonary diseases.A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.Mental health, serum biomarkers and survival in severe COPD: a pilot study.COPD subtypes identified by network-based clustering of blood gene expression.
P2860
Q23912391-6BAEC249-693A-4C3F-9418-BE85FD11F92EQ26766294-344AEF7A-82D7-45A0-A120-75399CE1D563Q26996356-394A8F22-90A1-4224-BDBA-DEFF6397A243Q28389786-A12FCA99-F490-4604-A880-0D7ACF2109C6Q28650506-F62BA5AD-4B4E-4A23-B249-9F7C2B140586Q29048648-7A1ED375-5A50-4656-80F8-EC4624DFF295Q29416995-3281FB8E-E1CF-4681-8BC4-80BC1FDF10D3Q31003434-994DA513-550E-46D2-951B-30968A60B435Q33568552-E5459BD2-D7E7-498B-868D-DC27D3FF8C84Q33586131-835F10EE-4AF3-4914-8866-1EA036A45691Q33612752-B88D6FFB-DB40-4B5F-AE25-86120D989830Q33705867-475A1A42-7521-4DC2-8EEC-9A1CEE8BC6A6Q33722392-9377ED96-BE60-4A8C-A344-B5E93EDE6858Q33757660-5B81F81A-52D7-45AE-8638-106C746489B4Q33796180-7EC0C13F-1201-4E59-A680-53ABA87B36B7Q33817613-EE63BCA2-54BF-4298-ACE8-362066576B06Q34005625-6145DA7B-06D0-4B3D-A0D6-5315EB803A3FQ34119539-832381BF-A038-4787-8E37-7A78D40AEB29Q34636461-CE67BA7C-C158-4A94-AE99-7954C15E160EQ35043468-1DF94E0D-887A-4424-8307-20FA03DEDB3BQ35077912-F42CFC3A-D00F-4DBE-ABA5-20BD151D6452Q35387845-9301DE63-2123-4E6F-AC0C-317B76CB4CCCQ35530179-45B02478-AFA7-40C1-9AF9-15DBF3E7A1DDQ35546827-04A417CC-E54E-4477-9068-870380A64B89Q35758923-D5C818CC-F107-4832-80CB-9AD8B8BF3065Q35766136-7E1104D3-9E9A-4812-9ABB-86A815FD1C24Q35794462-CEB0E779-B6FE-425C-A04A-FFEFA70A5840Q35835036-44189A28-ECE5-4BEE-80C9-E0CB3B110A99Q35964938-CB1938EC-DCB6-4B8B-8D10-1FEA9ED50375Q36000101-DC7B0CF8-F584-4424-B72D-5B5E25D0D9E2Q36036012-ED49C0BA-5FDA-409B-A16D-6BED0363CD8AQ36105708-83FF30E6-5042-401A-BBBD-773060EA1ABAQ36145085-DA32C0DF-8C57-4104-A601-0AC5BA137363Q36158231-50F6C0FD-E3FE-466D-9DD4-8444E48E39D9Q36272434-5BAC4C43-1184-4E37-BE09-A9D51AB249B2Q36300138-5846E5E2-476A-46CF-958A-A50D5353A4F9Q36378245-72471662-4280-4247-ADBC-9600358B53AEQ36411255-7E1774B2-2E5C-4CB3-9BB4-CFA65AFF9387Q36476007-B9416CB7-C6F2-4709-959E-FA3E94CCE442Q36600359-00137043-28EE-4CC7-AAEA-C031F85168FD
P2860
Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease
description
article
@en
im Mai 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2012
@uk
name
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@en
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@nl
type
label
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@en
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@nl
prefLabel
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@en
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@nl
P2093
P2860
P50
P921
P1476
Inflammatory Biomarkers Improv ...... Obstructive Pulmonary Disease
@en
P2093
Alvar Agustí
Annelyse Duvoix
Bartolome R. Celli
Bruce E. Miller
Courtney Crim
David A. Lomas
Edwin Silverman
Harvey Coxson
Julie Yates
Lisa D. Edwards
P2860
P304
P356
10.1164/RCCM.201110-1792OC
P407
P577
2012-05-15T00:00:00Z